What does this research mean for the field?

Circulating GDF11 is elevated in individuals with sarcopenia and contributes to age-related muscle loss by activating catabolic signaling pathways. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

The study aims to clarify the role of circulating GDF11 in aging and its association with sarcopenia.

February 28, 2026SHILAP Revista de lepidopterologíaOpen Access

Elevated circulating GDF11 and its role in age-related sarcopenia: insights from clinical, transcriptomic, and in vitro analyses

View Full Paper

Ask AI

Bookmark

Authors

RCRui Chen XDXin Dai HWHao Wang

Discussion

Member takes

Overview

Observational analyses reveal elevated GDF11 levels in sarcopenia, suggesting its involvement in muscle loss.

Key Points

The study aims to clarify the role of circulating GDF11 in aging and its association with sarcopenia.
Quantified circulating GDF11 levels in participants categorized by age and sarcopenia status.
Applied propensity score matching and multivariable logistic regression to determine risk factors for sarcopenia.
Conducted Mendelian randomization and mediation analyses to uncover causal relationships.
Performed transcriptomic analyses using muscle datasets and protein–protein interaction networks.
Assessed effects of recombinant GDF11 treatment on myotube signaling and atrophy markers.
Higher circulating GDF11 levels were found in older adults, especially those with sarcopenia.
GDF11 identified as an independent risk factor for sarcopenia through logistic regression.
Mendelian randomization indicated physical activity has a protective effect against sarcopenia traits.
GDF11 mRNA levels in muscle remained stable, suggesting its source is not muscle tissue.
Treatment with GDF11 activated SMAD3 and increased levels of muscle atrophy markers in myotubes.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/69a285aa0a974eb0d3c00a57 https://doi.org/10.3389/fragi.2026.1736069

View Full Paper

Ask AI

Bookmark

February 28, 2026SHILAP Revista de lepidopterologíaOpen Access

Elevated circulating GDF11 and its role in age-related sarcopenia: insights from clinical, transcriptomic, and in vitro analyses

View Full Paper

Ask AI

Bookmark

Authors

RCRui Chen XDXin Dai HWHao Wang

Discussion

Member takes

Overview

Observational analyses reveal elevated GDF11 levels in sarcopenia, suggesting its involvement in muscle loss.

Key Points

The study aims to clarify the role of circulating GDF11 in aging and its association with sarcopenia.
Quantified circulating GDF11 levels in participants categorized by age and sarcopenia status.
Applied propensity score matching and multivariable logistic regression to determine risk factors for sarcopenia.
Conducted Mendelian randomization and mediation analyses to uncover causal relationships.
Performed transcriptomic analyses using muscle datasets and protein–protein interaction networks.
Assessed effects of recombinant GDF11 treatment on myotube signaling and atrophy markers.
Higher circulating GDF11 levels were found in older adults, especially those with sarcopenia.
GDF11 identified as an independent risk factor for sarcopenia through logistic regression.
Mendelian randomization indicated physical activity has a protective effect against sarcopenia traits.
GDF11 mRNA levels in muscle remained stable, suggesting its source is not muscle tissue.
Treatment with GDF11 activated SMAD3 and increased levels of muscle atrophy markers in myotubes.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/69a285aa0a974eb0d3c00a57 https://doi.org/10.3389/fragi.2026.1736069

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark